news
Eli Lilly, Novo Nordisk win antitrust suit against compound pharmacy
A federal judge sided with Eli Lilly and Novo Nordisk, dismissing an antitrust lawsuit brought by a compounding pharmacy. The lawsuit alleged the pharma giants were stifling competition in the GLP-1 market. This win protects the big pharma hold on these popular drugs.
A federal judge sided with Eli Lilly and Novo Nordisk, dismissing an antitrust lawsuit brought by a compounding pharmacy. The lawsuit alleged the pharma giants were stifling competition in the GLP-1 market. This win protects the big pharma hold on these popular drugs.
The architecture take
The big pharma playbook for GLP-1s just got a legal boost. This isn't about fair competition for 'innovation' – it's about control over a massive market. When you have drugs like Ozempic and Mounjaro bringing in billions, you don't want anyone else muscling in on the supply or the pricing. This ruling effectively says, 'Yeah, we can keep the compounders out.' For consumers, it means continued high prices and limited access to alternatives for drugs impacting blood sugar and weight management. I'd watch to see how this emboldens other pharma companies with blockbuster drugs to quash any perceived threats from smaller players. The legal system just reinforced the existing power dynamic, and your options for getting these compounds just narrowed again.